Skip to content
value.today

Garuda Therapeutics, Inc.

🇺🇸 Natick, Massachusetts, USABiotechnologyFounded 2021

Formerly L Stem, LLC

Total raised
$158 M
3 rounds on record
Latest round
$48 M
Oct 2024
First round on record
Sep 2021
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Garuda Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2024$48 MNo. 3$10 to $50 million

Garuda Therapeutics, Inc.: Raise no. 3, Oct 2024

Investors in this round

16 investors had bought by the notice of Oct 31, 2024: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$48 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Adam Craig · Executive Officer, Director
  • David Kirske · Executive Officer
  • Carl Gordon · Director
  • Eric Aguiar · Director
  • Geoff Meyerson · Director
  • Rahul Singhvi · Director
  • Raymond Kelleher · Director
  • Steve Liapis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Adam Craig, President and CEO. Source: SEC Form D, newest notice filed Oct 31, 2024. Read the notice at the SEC.

equity, optionsSEC
Jan 2023$62 MNo. 2$50 to $250 million

Garuda Therapeutics, Inc.: Raise no. 2, Jan 2023

Investors in this round

13 investors had bought by the notice of Feb 3, 2023: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$62 M of $63 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dhvanit I Shah · Executive Officer, Director · Chief Executive Officer and President
  • Carl I Gordon · Director
  • Daniel I Janse · Director
  • Eric I Aguiar · Director
  • Laurence I Reid · Director
  • Rahul I Singhvi · Director
  • Raymond I Kelleher · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Dhvanit I. Shah, Chief Executive Officer and President. Source: SEC Form D, newest notice filed Feb 3, 2023. Read the notice at the SEC.

equitySEC
Sep 2021$48 MNo. 1$10 to $50 million

Garuda Therapeutics, Inc.: Raise no. 1, Sep 2021

Investors in this round

23 investors had bought by the notice of Sep 24, 2021: 23 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$48 M of $72 M offered; $24 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,000,000
Finders' fees
none
Paid to its own people
$970,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dhvanit I Shah · Executive Officer, Director · Chief Executive Officer of the Issuer
  • Carl I Gordon · Director
  • Eric I Aguiar · Director
  • Rahul I Singhvi · Director
  • Shaan I Gandhi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Locust Walk Partners, LLC · broker-dealer Locust Walk Securities, LLC (CRD 156174) · Boston, MassachusettsSold in all US states, and outside the US

Remarks in the notice

  • On the use of proceeds: “for founders loans, expense reimbursement and other contributions made by the Chief Executive Officer”

Signed by Dhvanit I. Shah, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 24, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Garuda Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2024).

    SEC Form D · Oct 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2024

That is all the official record says: Garuda Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Garuda Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 23 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Garuda Therapeutics, Inc.
NameRoleNamed in
Adam CraigExecutive officerOct 2024
David KirskeExecutive officerOct 2024
Dhvanit I ShahChief Executive Officer and PresidentFeb 2023
Adam CraigDirectorOct 2024
Carl GordonDirectorOct 2024
Eric AguiarDirectorOct 2024
Geoff MeyersonDirectorOct 2024
Rahul SinghviDirectorOct 2024
Raymond KelleherDirectorOct 2024
Steve LiapisDirectorOct 2024
Carl I GordonDirectorFeb 2023
Daniel I JanseDirectorFeb 2023
Dhvanit I ShahChief Executive Officer and PresidentFeb 2023
Eric I AguiarDirectorFeb 2023
Laurence I ReidDirectorFeb 2023
Rahul I SinghviDirectorFeb 2023
Raymond I KelleherDirectorFeb 2023
Shaan I GandhiDirectorSep 2021